MedTrace Logo

Substance Abuse Pre-Treatment Screening Study

NCT00439049 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 7500

Last updated 2023-12-20

No results posted yet for this study

Summary

The overarching goal of this project is to have a consolidated consent and evaluation procedure that will lead potential subjects to the most appropriate clinical trial or human laboratory study (and its consent process) for their presenting concerns or interests. A second purpose is to have a consolidated intake data base on which secondary analyses can be conducted.

Conditions

  • Cocaine Abuse
  • Cocaine Dependence
  • Opiate Dependence
  • Alcohol Dependence
  • Substance Abuse

Interventions

DRUG

modafinil

400 mg daily

DRUG

d-amphetamine

60mg daily

DRUG

L-Dopa

800/200mg daily

DRUG

Naltrexone

50mg daily

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Joy M. Schmitz, PhD · The University of Texas Health Science Center, Houston

  • Frederick G Moeller, MD · The University of Texas Health Science Center, Houston

  • Angela L Stotts, PhD · The University of Texas Health Science Center, Houston

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00439049 on ClinicalTrials.gov